Clonidine Pharmacology

Quick Answer

Clonidine is a selective alpha-2 (α2) adrenergic receptor agonist with central sympatholytic, sedative, and analgesic properties that make it valuable in perioperative medicine. It is an imidazoline derivative that acts primarily in the brainstem to inhibit sympathetic outflow, producing dose-dependent reductions in blood pressure, heart rate, and circulating catecholamines. The drug is classified as an imidazoline-derivative α2 agonist, distinguishing it from phenethylamine derivatives like dexmedetomidine. Clonidine's mechanism involves selective binding to α2A and α2C adrenergic receptors in the dorsal horn of the spinal cord and locus coeruleus, resulting in enhanced descending inhibitory pathways for pain and reduced noradrenergic neurotransmission.

In anaesthetic practice, clonidine serves multiple roles: preoperative anxiolysis and sympatholysis (100-200 mcg orally or 1-2 mcg/kg IV), intraoperative adjunct for balanced anaesthesia (1-2 mcg/kg IV), treatment of perioperative hypertension, and as an adjuvant in neuraxial analgesia (15-30 mcg epidural or 30-100 mcg intrathecal). The onset of action is 30-60 minutes orally, 10-15 minutes IV, with a prolonged duration of action due to high lipid solubility and extensive distribution. Elimination is primarily renal (40-60% unchanged) with an elimination half-life of 12-16 hours. Key perioperative benefits include reduced anaesthetic requirements (15-30% MAC reduction), improved haemodynamic stability, reduced postoperative pain scores, and decreased opioid consumption (25-40% reduction). Comparison with dexmedetomidine shows clonidine has longer onset, more prolonged action, less potent sedative effects, and significantly lower cost, making it suitable for ambulatory and resource-limited settings. [1-15]

Pharmacology Overview

Drug Classification and History

Clonidine belongs to the imidazoline derivative class of centrally acting alpha-2 adrenergic receptor agonists. The drug was initially developed in the 1960s by Boehringer Ingelheim as a nasal decongestant, but its potent hypotensive effects were discovered accidentally during clinical trials. It was subsequently approved for hypertension treatment in 1966 and became widely used as an antihypertensive agent before the advent of newer drug classes.

The recognition of clonidine's analgesic, sedative, and sympatholytic properties in the 1970s and 1980s led to its adoption in anaesthetic practice. Today, its primary perioperative applications include premedication, intraoperative haemodynamic control, postoperative pain management (particularly as a neuraxial adjuvant), and management of postoperative shivering. Clonidine is listed on the World Health Organization's List of Essential Medicines and remains one of the most cost-effective alpha-2 agonists available.

Clonidine differs from dexmedetomidine in chemical structure (imidazoline vs phenethylamine), pharmacokinetics (longer half-life, slower onset), and clinical profile (less potent sedation, longer duration). This structural and pharmacological comparison is a high-yield topic in ANZCA examinations. [1-8]

Chemical Structure and Physicochemical Properties

Clonidine (clonidine hydrochloride) is an imidazoline derivative with the molecular formula C9H9Cl2N3 and molecular weight of 230.1 Da (as free base). The IUPAC name is N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine. The molecule consists of a 2,6-dichlorophenyl ring attached to an imidazoline ring, creating a highly lipophilic structure with excellent membrane penetration. [9-11]

Key Physicochemical Properties:

The high lipid solubility of clonidine is a critical feature that enables:

1. Rapid penetration of the blood-brain barrier for central effects
2. Efficient absorption from the gastrointestinal tract
3. Penetration into the spinal cord when administered neuraxially
4. Distribution into adipose tissue, contributing to prolonged duration

Clonidine is available as oral tablets (25, 75, 150 mcg), transdermal patches (delivering 100-300 mcg/day), and IV formulations for perioperative use. The drug is stable in solution and compatible with common IV fluids, though it should not be mixed with alkaline solutions. [12-15]

Comparison: Clonidine vs Dexmedetomidine

Clinical Implications of Differences:

1. Onset and Duration: Clonidine's slower onset and longer duration make it ideal for prolonged procedures and chronic pain, while dexmedetomidine's rapid onset/offset suits titratable sedation and short procedures.

2. Route Flexibility: Clonidine's excellent oral bioavailability enables outpatient premedication and chronic pain management; dexmedetomidine requires IV administration.

3. Sedative Depth: Dexmedetomidine produces more profound, titratable sedation allowing "cooperative sedation"; clonidine produces lighter, less titratable sedation.

4. Cost: Clonidine is approximately 50-100 times less expensive than dexmedetomidine, making it the preferred choice in cost-sensitive environments.

5. Haemodynamic Stability: Both drugs cause hypotension and bradycardia, but dexmedetomidine's effects are more rapidly reversible. [16-25]

Mechanism of Action

Alpha-2 Adrenergic Receptor Pharmacology

Clonidine exerts its pharmacological effects primarily through selective activation of alpha-2 (α2) adrenergic receptors, with minimal activity at alpha-1 (α1) receptors. The α2:α1 selectivity ratio is approximately 220:1, distinguishing it from non-selective agents and explaining its characteristic clinical profile. [26-28]

Alpha-2 Adrenergic Receptor Subtypes:

Three α2 receptor subtypes have been identified, each with distinct tissue distribution and functional roles:

Clonidine has high affinity for all three subtypes but preferentially activates α2A receptors in the central nervous system, mediating its sedative, analgesic, and sympatholytic effects. [29-31]

Central Mechanisms

1. Sympatholysis (Hypotensive Effect):

The primary antihypertensive mechanism involves action at the nucleus tractus solitarius (NTS) and ventrolateral medulla (VLM) in the brainstem:

• Activation of α2A receptors on presynaptic terminals of noradrenergic neurons in the locus coeruleus
• Reduced release of norepinephrine (noradrenaline) from sympathetic nerve terminals
• Decreased sympathetic outflow to the periphery
• Reduced circulating catecholamines (plasma norepinephrine falls by 40-60%)
• Unopposed parasympathetic tone leading to bradycardia

This central sympatholytic effect produces:

• Reduced systemic vascular resistance (15-25% decrease)
• Decreased heart rate (10-20% decrease)
• Reduced renin release
• No change or mild reduction in cardiac output (unlike direct vasodilators)
• Minimal postural hypotension [32-35]

2. Analgesic Mechanism:

Clonidine produces analgesia through multiple spinal and supraspinal mechanisms:

• Spinal Cord (Dorsal Horn): Activation of α2A receptors on postsynaptic neurons in lamina II (substantia gelatinosa) of the dorsal horn inhibits transmission of nociceptive signals. This is enhanced by α2 receptor-mediated inhibition of substance P release from primary afferent neurons.
• Descending Inhibitory Pathways: Enhanced activity of descending noradrenergic pathways from the locus coeruleus to the dorsal horn
• Supraspinal Effects: Action in periaqueductal gray (PAG) and other brainstem nuclei modulate pain perception

When administered neuraxially, clonidine produces potent segmental analgesia without significant motor or sensory blockade, making it an ideal adjuvant to local anaesthetics and opioids. [36-40]

3. Sedative Mechanism:

Sedation results from α2A receptor activation in the locus coeruleus:

• The locus coeruleus is the primary noradrenergic nucleus in the brain
• α2 receptor activation inhibits firing of locus coeruleus neurons
• Reduced noradrenergic transmission to the cerebral cortex and limbic system
• Result: Decreased arousal, anxiolysis, and sleep-promoting effects

This mechanism differs from GABA-mediated sedation (benzodiazepines, propofol) and produces a more natural sleep-like state with preserved respiratory drive and easier arousal. [41-43]

Peripheral Mechanisms

1. Platelet Function: Activation of α2A receptors on platelets inhibits adenylyl cyclase, potentially reducing platelet aggregation and offering antithrombotic effects. [44]

2. Insulin Secretion: α2 receptor activation inhibits insulin release from pancreatic beta cells, potentially causing mild hyperglycaemia at higher doses. [45]

3. Renal Effects: Reduced renin release and mild reduction in renal vascular resistance; generally preserves glomerular filtration rate despite reduced blood pressure. [46]

Pharmacokinetic Principles

Absorption

Clonidine demonstrates excellent bioavailability across multiple routes of administration:

Oral Administration:

• Bioavailability: 75-95% (complete absorption)
• Onset: 30-60 minutes (hypotensive effect)
• Peak plasma concentration: 1-3 hours post-dose
• Food does not significantly affect absorption

Intravenous Administration:

• Bioavailability: 100% by definition
• Onset: 10-15 minutes (hypotensive effect)
• Peak effect: 20-30 minutes

Transdermal Administration:

• Patch delivers 100-300 mcg/day continuously
• Onset: 2-3 days for steady-state blood pressure reduction
• Steady-state plasma concentration: 48-72 hours
• Reservoir effect continues for 24-48 hours after patch removal

Neuraxial Administration:

• Epidural: Onset 15-30 minutes; duration 4-8 hours
• Intrathecal: Onset 10-20 minutes; duration 6-12 hours
• CSF concentrations after neuraxial dosing are 100-1000x plasma concentrations

Other Routes:

• Intramuscular: Similar to IV but slower onset (20-30 minutes)
• Nasal: Experimental use for rapid absorption; biovariable
• Ophthalmic: Minimal systemic absorption at standard doses [47-54]

Distribution

Clonidine's high lipid solubility enables extensive distribution into:

• Adipose tissue (contributing to prolonged elimination)
• Brain and spinal cord (CNS effects)
• Myocardium (direct cardiac effects)
• Kidney, liver, and other well-perfused organs

The large volume of distribution (2-3 L/kg) reflects extensive tissue binding. After neuraxial administration, clonidine spreads rostrally in the CSF, potentially causing late-onset sedation and hypotension. [55-59]

Metabolism

Clonidine undergoes moderate hepatic metabolism with two primary pathways:

1. Hydroxylation (major pathway - 40-50% of dose):

• Cytochrome P450 enzymes (primarily CYP2D6)
• Formation of para-hydroxyclonidine and other hydroxylated metabolites
• These metabolites are inactive

2. Conjugation:

• Glucuronidation of parent drug and metabolites
• Increases water solubility for renal excretion

Metabolic Considerations:

• Hepatic impairment: May reduce clearance by 30-50%; dose adjustment may be needed
• CYP2D6 genetic polymorphisms: May affect metabolism rate but clinical significance is limited
• Drug interactions: Inhibitors of CYP2D6 may increase clonidine levels

Approximately 40-60% of an oral dose is excreted unchanged in urine, indicating that metabolism is not the primary elimination pathway. [60-63]

Elimination

Renal Elimination: Clonidine is eliminated primarily by renal excretion of unchanged drug and metabolites. The drug undergoes both glomerular filtration and active tubular secretion. Renal impairment significantly affects elimination:

Important Clinical Implications:

1. Accumulation occurs with repeated dosing due to long half-life
2. Therapeutic effects persist for 6-8 hours after single IV dose despite 12-16 hour half-life
3. Rebound hypertension can occur 24-48 hours after abrupt cessation
4. Dose reduction required in renal impairment
5. Not effectively removed by dialysis due to large Vd [64-68]

Kinetic Summary for Perioperative Use

Pharmacodynamics: Systemic Effects

Cardiovascular Effects

Blood Pressure: Clonidine produces dose-dependent reductions in arterial blood pressure through multiple mechanisms:

• Reduced Systemic Vascular Resistance: Primary mechanism; SVR falls 15-25%
• Reduced Cardiac Output: Mild reduction (10-15%) due to bradycardia
• Reduced Venous Return: Mild venodilation
• Effect on Different Vascular Beds:
  • Skin and splanchnic vessels: Vasodilation (warming)
  • Renal vessels: Minimal change (preserved autoregulation)
  • Cerebral vessels: Minimal direct effect

The hypotensive response follows a characteristic pattern:

• Initial phase (0-2 hours): Maximal blood pressure reduction
• Equilibrium phase (2-8 hours): Partial tolerance develops
• Chronic phase: Sustained modest reduction in BP

Heart Rate: Bradycardia is a consistent finding with clonidine administration:

• Mechanism: Increased vagal tone plus reduced sympathetic tone
• Magnitude: 10-20% reduction (10-20 bpm decrease)
• Time course: Begins within 15-30 minutes, peaks at 1-2 hours
• Clinical significance: Usually well-tolerated; may be problematic in patients with conduction disease

Cardiac Output and Contractility:

• Cardiac output: Mild reduction (10-15%) due to heart rate decrease
• Stroke volume: Generally preserved or slightly reduced
• Contractility: Direct myocardial effects are minimal at clinical doses
• Regional perfusion: Preserved coronary, cerebral, and renal perfusion

Haemodynamic Stability: Clonidine improves haemodynamic stability during anaesthesia by:

• Blunting sympathetic responses to laryngoscopy and intubation
• Reducing pressor response to surgical stimulation
• Attenuating catecholamine surges
• Maintaining stable heart rate during periods of noxious stimulation [69-75]

Central Nervous System Effects

Sedation:

• Onset: 15-30 minutes after IV administration
• Depth: Moderate; patient remains arousable
• Characteristics: "Cooperative sedation" - patient may open eyes and respond to commands but drifts back to sleep
• Duration: 4-8 hours depending on dose
• Respiratory effects: Minimal respiratory depression; preserved CO2 response

Anxiolysis:

• Significant reduction in anxiety scores preoperatively
• Comparable to benzodiazepines for anxiolytic effect
• No amnesia (unlike benzodiazepines)
• Improves patient cooperation during regional anaesthesia

Analgesia:

• Systemic clonidine: Modest analgesic effect; primarily augments other analgesics
• Neuraxial clonidine: Potent, dose-dependent segmental analgesia
• Mechanism: Enhanced descending inhibitory pathways, reduced substance P release
• Duration: Prolongs effect of local anaesthetics and opioids when used as adjuvant

Other CNS Effects:

• Reduced postoperative shivering (thermoregulatory effect)
• Attenuation of stress response (reduced cortisol, catecholamines)
• Possible neuroprotective effects (experimental)
• Does not lower seizure threshold [76-82]

Respiratory Effects

Clonidine has minimal effects on respiratory function, making it safe in patients with respiratory disease:

• Ventilatory Response to CO2: Preserved; no significant shift in CO2 response curve
• Airway Resistance: Minimal bronchodilatory effect via central mechanism
• Upper Airway Tone: May reduce upper airway tone; caution in obstructive sleep apnoea
• Respiratory Rate: Mild reduction (2-4 breaths/min) but adequate ventilation maintained
• Protective Reflexes: Cough and laryngeal reflexes preserved
• Sleep Apnoea: May worsen obstructive sleep apnoea; screen patients preoperatively

This respiratory profile contrasts favorably with opioids and benzodiazepines, which produce dose-dependent respiratory depression. [83-85]

Metabolic and Endocrine Effects

Stress Response: Clonidine significantly attenuates the surgical stress response:

• Reduced plasma catecholamines (40-60% reduction)
• Reduced plasma cortisol (30-40% reduction)
• Reduced plasma renin and aldosterone
• Reduced hyperglycaemic response
• Attenuated protein catabolism

Glucose Homeostasis:

• Inhibition of insulin secretion (α2 receptor-mediated)
• Mild hyperglycaemia may occur, especially in diabetics
• Monitor blood glucose in diabetic patients

Other Endocrine Effects:

• Reduced growth hormone release (minimal clinical significance)
• No effect on thyroid function
• Reduced ADH release [86-89]

Gastrointestinal Effects

• Gastric Emptying: May delay gastric emptying slightly
• Intestinal Motility: Reduces motility; caution in ileus
• Salivary Secretions: Mild reduction
• Nausea and Vomiting: May reduce PONV through reduced catecholamines and antiemetic effect [90]

Clinical Pharmacology

Perioperative Indications and Dosing

1. Premedication (Oral or IV)

Indications:

• Anxiolysis for anxious patients
• Premedication for patients at risk of perioperative hypertension
• Patients on chronic clonidine (continue preoperatively)
• Opioid-sparing strategy

Dosing:

• Oral: 100-200 mcg (2-3 mcg/kg) 60-90 minutes preoperatively
• IV: 1-2 mcg/kg 30-60 minutes preoperatively
• Intramuscular: 2-3 mcg/kg 45-60 minutes preoperatively

Benefits:

• Reduced anxiety without respiratory depression
• Reduced preoperative hypertension
• Reduced anaesthetic requirements
• Postoperative analgesia
• Reduced shivering [91-93]

2. Intraoperative Adjunct

Indications:

• Control of intraoperative hypertension
• Management of sympathetic responses (laryngoscopy, surgical stimulation)
• Component of balanced anaesthesia technique
• During wake-up tests in spine surgery

Dosing:

• Bolus: 1-3 mcg/kg IV
• Infusion: 0.5-2 mcg/kg/hour (rarely used due to long half-life)

Benefits:

• 15-30% reduction in MAC of volatile agents
• Reduced opioid requirements (25-40% reduction)
• Improved haemodynamic stability
• Smooth emergence without significant respiratory depression [94-96]

3. Neuraxial Adjuvant

Epidural Clonidine:

• Dose: 15-30 mcg (diluted in local anaesthetic solution)
• Onset: 15-30 minutes
• Duration: Extends local anaesthetic effect by 2-4 hours
• Benefits: Enhanced analgesia, reduced opioid requirements, improved block quality
• Risks: Hypotension, bradycardia, sedation, urinary retention

Intrathecal Clonidine:

• Dose: 15-75 mcg (usually 30-50 mcg)
• Added to local anaesthetic/spinal opioid
• Prolongs spinal anaesthesia by 1-2 hours
• Significant risk of hypotension, bradycardia, sedation at higher doses
• Use lower doses (15-30 mcg) in elderly or frail patients

Clinical Pearls for Neuraxial Use:

• Always dilute clonidine in the local anaesthetic solution
• Monitor haemodynamics closely for 2-4 hours after administration
• Have vasopressors readily available
• Avoid in patients with significant baseline hypotension or bradycardia
• Contraindicated in hypovolaemic patients [97-103]

4. Postoperative Analgesia

Oral Clonidine:

• 100-200 mcg every 8-12 hours as adjunct to multimodal analgesia
• Particularly useful in patients with chronic pain, opioid tolerance, or neuropathic pain components
• Reduces opioid consumption by 25-40%

Transdermal Clonidine:

• Patch applied preoperatively delivers continuous analgesia for 7 days
• Useful for prolonged postoperative pain (orthopaedic, thoracic surgery)
• Patch 100-300 mcg/day applied 48-72 hours preoperatively

Regional Techniques:

• Continuous epidural with clonidine 10-30 mcg/hour (specialist use)
• Peripheral nerve block adjuvant (limited evidence) [104-106]

5. Treatment of Postoperative Shivering

Dosing:

• 75-150 mcg IV
• Onset: 5-10 minutes
• Efficacy: 70-90% success rate
• Mechanism: Central thermoregulatory effect plus reduced catecholamines

Advantages:

• No respiratory depression (unlike meperidine)
• Analgesic effect
• Minimal nausea (unlike meperidine) [107,108]

Contraindications

Drug Interactions

Special Populations

Paediatric Patients

Pharmacokinetic Differences:

• Higher volume of distribution (3-4 L/kg)
• Faster elimination (half-life 8-12 hours in children)
• Enhanced CNS sensitivity to sedative effects

Clinical Use:

• Premedication: 2-4 mcg/kg orally 45-60 minutes preoperatively
• Caudal/epidural adjuvant: 1-2 mcg/kg
• Postoperative analgesia: 1-2 mcg/kg every 8 hours

Risks:

• Higher risk of sedation and respiratory depression
• Hypotension more pronounced
• Monitor closely for 4-6 hours after neuraxial administration
• FDA warning regarding epidural use in children due to risk of hypotension and respiratory depression [109-111]

Elderly Patients

Considerations:

• Enhanced sensitivity to hypotensive and sedative effects
• Reduced clearance (half-life may extend to 20-30 hours)
• Increased risk of falls (orthostatic hypotension)
• Impaired thermoregulation (increased shivering risk without prophylaxis)

Dosing Adjustments:

• Start at lower end of dosing range (50% of standard adult dose)
• Titrate slowly with careful monitoring
• Avoid neuraxial doses >30 mcg
• Monitor for prolonged sedation postoperatively [112]

Pregnancy and Lactation

Pregnancy:

• Category C (FDA); crosses placenta
• Limited data on safety in pregnancy
• May cause fetal bradycardia at high doses
• Can be used for hypertension in pregnancy if benefits outweigh risks
• Neuraxial use: Limited safety data; use lowest effective dose

Labour and Delivery:

• Can be used for labour analgesia in combination with opioids
• Epidural clonidine 15-30 mcg provides effective analgesia
• Monitor fetal heart rate for bradycardia

Lactation:

• Excreted in breast milk (concentration ~50% of maternal plasma)
• Compatible with breastfeeding per AAP guidelines
• Monitor infant for sedation, poor feeding [113,114]

Renal Impairment

• Reduced clearance; dose adjustment required (see Pharmacokinetics section)
• Neuraxial clonidine may have prolonged effect
• Monitor for accumulation with repeated dosing
• Consider alternative agents in severe renal failure [115]

Hepatic Impairment

• Moderate reduction in clearance
• Start with reduced dose (50-75% of normal)
• Monitor for prolonged sedation and hypotension [116]

Adverse Effects and Complications

Common Adverse Effects

Serious Adverse Effects

1. Severe Bradycardia and AV Block:

• Incidence: 1-5% with high doses or combination with other bradycardic drugs
• Risk factors: Pre-existing conduction disease, beta-blocker use, elderly
• Management: Atropine 0.5-1 mg IV; glycopyrrolate may be less effective; temporary pacing if refractory; discontinue clonidine

2. Profound Hypotension:

• Incidence: 5-10% with neuraxial use; 1-3% with systemic use
• Risk factors: Hypovolaemia, concomitant vasodilators, neuraxial anaesthesia
• Management: IV fluids, Trendelenburg position, vasopressors (phenylephrine, ephedrine); consider invasive monitoring

3. Respiratory Depression (Rare):

• Usually occurs with high neuraxial doses or combination with other sedatives
• Risk factors: Obstructive sleep apnoea, obesity, COPD, concomitant opioids
• Management: Supportive care; naloxone ineffective (not an opioid); consider flumazenil if benzodiazepines co-administered

4. Rebound Hypertension (Withdrawal):

• Occurs 24-48 hours after abrupt cessation in chronic users
• Mechanism: Upregulation of α2 receptors and norepinephrine hypersensitivity
• Severity: Can be severe (BP >180/110 mmHg)
• Prevention: Gradual taper over 7-14 days
• Treatment: Restart clonidine or use alternative antihypertensives; labetalol or nicardipine for acute control

5. CNS Effects:

• Confusion, hallucinations (rare, usually in elderly)
• Depression (rare)
• Seizures (very rare) [117-125]

Clonidine Withdrawal Syndrome

Features:

• Rebound hypertension (most common)
• Tachycardia
• Headache
• Sweating
• Tremors
• Anxiety, restlessness
• Insomnia
• Rarely: hypertensive encephalopathy, myocardial infarction, stroke

Management:

1. Prevention: Never discontinue chronic clonidine abruptly; taper over 7-14 days
2. Recognition: Monitor BP and HR for 24-48 hours after cessation
3. Treatment:
   • Restart clonidine if possible
   • Alternative antihypertensives (ACE inhibitors, calcium channel blockers)
   • Beta-blockers for tachycardia (after BP controlled)
   • Phentolamine or nitroprusside for severe hypertension

Perioperative Considerations:

• Patients on chronic clonidine should receive their usual dose preoperatively (morning of surgery with sip of water)
• If NPO status prolonged, consider transdermal patch or IV clonidine
• Restart oral clonidine as soon as oral intake tolerated postoperatively
• If clonidine cannot be restarted within 24 hours, use alternative antihypertensive strategy [126-129]

Australian/NZ Specific Considerations

TGA-Approved Formulations

Clonidine is TGA-approved in Australia in the following formulations:

Availability:

• Oral tablets and transdermal patches are PBS-listed for hypertension
• Injection formulation is available through hospital pharmacies for perioperative use
• Cost: Tablets approximately $10-20/month; injection approximately $5-10 per ampoule

PBS Listing and Restrictions

PBS-Listed Indications:

1. Hypertension: Standard PBS authority not required for tablets
2. ADHD (Paediatric): Authority required for patients <18 years
3. Cancer Pain: Authority required for palliative care patients
4. Tourette Syndrome: Authority required

Perioperative Use:

• Perioperative clonidine is NOT specifically PBS-listed
• Hospital funding through drug budgets
• Cost-effective compared to dexmedetomidine for appropriate indications

ANZCA Guidelines and References

ANZCA PS15 (Guidelines for the Management of Evolving Regional Anaesthesia):

• Acknowledges clonidine as an effective adjuvant for neuraxial techniques
• Recommends careful monitoring when neuraxial clonidine used
• Notes risk of hypotension, bradycardia, and sedation

ANZCA PS02 (Guidelines for Sedation and/or Analgesia for Diagnostic and Interventional Medical, Dental or Surgical Procedures):

• Clonidine can be used as a component of monitored sedation
• Requires appropriate monitoring including pulse oximetry and blood pressure
• Recommendations for trained personnel and resuscitation equipment

Australian and New Zealand College of Anaesthetists:

• Endorses evidence-based use of alpha-2 agonists in perioperative care
• Emphasizes cost-effectiveness of clonidine in appropriate clinical scenarios
• Recommends gradual tapering of chronic clonidine to prevent rebound hypertension [130-132]

Clinical Practice in Australia/NZ

Common Perioperative Applications:

1. Cardiac Surgery: Preoperative anxiolysis and sympatholysis; reduces catecholamine surge
2. Thoracic Surgery: Epidural adjuvant for enhanced analgesia
3. Spine Surgery: Intraoperative wake-up test facilitation
4. Ambulatory Surgery: Oral premedication for anxiety and haemodynamic control
5. Chronic Pain: Transdermal patch for prolonged postoperative pain

Rural and Remote Considerations:

• Clonidine tablets are widely available in rural hospitals and health services
• Injection formulation may be limited in very remote settings
• Oral premedication can be given in preadmission clinic for patients travelling from remote areas
• Cost-effectiveness makes it suitable for resource-limited settings [133,134]

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Considerations

Health Context: Aboriginal and Torres Strait Islander Australians experience significantly higher rates of chronic diseases that may impact perioperative management with clonidine. Hypertension, cardiovascular disease, and chronic kidney disease prevalence is 2-3 times higher than in non-Indigenous Australians, necessitating careful assessment of baseline cardiovascular and renal function before clonidine administration.

Cardiovascular Disease: Higher rates of ischaemic heart disease, heart failure, and peripheral vascular disease in Indigenous populations require careful evaluation before using sympatholytic agents. Baseline hypotension and bradycardia should be identified, and lower starting doses of clonidine (50% of standard) should be considered in patients with known cardiac disease. Close haemodynamic monitoring is essential, particularly in neuraxial applications where profound hypotension can occur.

Chronic Kidney Disease: The elevated prevalence of chronic kidney disease in Indigenous communities (estimated glomerular filtration rate <60 mL/min/1.73m² in 18% of adults) necessitates dose adjustment of clonidine, which is primarily renally eliminated. In patients with eGFR 30-60 mL/min/1.73m², reduce dose by 50%; in severe renal impairment (eGFR <30), reduce by 50-75% or consider alternative agents.

Access and Equity: Remote Indigenous communities often have limited access to specialist anaesthesia services. Clonidine's availability in oral and injectable forms makes it suitable for use in remote settings, but requires:

• Adequate training of rural medical officers and nurse practitioners in perioperative use
• Availability of resuscitation equipment and vasopressor medications
• Clear protocols for monitoring and managing hypotension/bradycardia
• Telemedicine support from tertiary centres when needed

Cultural Safety: Perioperative care for Aboriginal and Torres Strait Islander patients should involve culturally safe communication:

• Involve Aboriginal Health Workers (AHWs) or Aboriginal Liaison Officers (ALOs) in preoperative education
• Explain anticipated effects (dry mouth, drowsiness, potential blood pressure changes) in culturally appropriate language
• Recognize that family and community involvement in healthcare decisions is important; involve family members in discussions about medication use and postoperative care where appropriate
• Respect cultural beliefs about medication and healing

Medication Adherence: Postoperative continuation of clonidine (particularly for chronic pain or hypertension) requires consideration of:

• Cost and PBS access (clonidine is affordable but requires ongoing prescriptions)
• Distance from pharmacies in remote communities
• Cultural acceptability of ongoing medication use
• Integration with traditional healing practices when appropriate [135-138]

Māori Health Considerations (New Zealand)

Health Context: Māori experience significant health disparities compared to non-Māori New Zealanders, including higher rates of cardiovascular disease (60% higher), diabetes (3x higher), and chronic kidney disease. These comorbidities influence perioperative clonidine use and require tailored approaches.

Whānau Involvement: Māori healthcare is whānau-centred, with collective decision-making valued over individual autonomy. Perioperative discussions about clonidine use should:

• Include whānau members in consent and treatment decisions
• Provide information in te reo Māori when preferred
• Respect tikanga (customary practices) and manaakitanga (hospitality, care)
• Allow time for family consultation before procedures

Cultural Safety:

• Māori Health Workers should be involved in care coordination where available
• Recognize that previous negative experiences with healthcare may affect trust
• Acknowledge inequities in health outcomes and commit to providing excellent care
• Consider that Māori may have higher pain tolerance expression or different communication styles about pain

Comorbidity Management: Given elevated rates of diabetes and cardiovascular disease in Māori populations:

• Monitor blood glucose closely (clonidine may impair insulin secretion)
• Assess baseline ECG for conduction abnormalities before clonidine
• Consider cardiac stress testing if significant risk factors present
• Optimize cardiovascular status preoperatively

Medication Access: Clonidine is fully subsidized in New Zealand (no patient co-payment), which supports adherence and equity of access. Ensure patients understand the importance of continuing chronic clonidine and the risks of abrupt discontinuation. [139-141]

Remote and Rural Considerations

Resource-Limited Settings: In remote Australian communities and rural New Zealand hospitals:

• Clonidine is highly cost-effective compared to dexmedetomidine
• Oral premedication can be given before transfer to regional centres
• Limited monitoring capabilities require careful patient selection
• Avoid neuraxial clonidine if continuous monitoring unavailable

Retrieval Medicine: Clonidine may be used during interhospital transfer for:

• Sedation in ventilated patients (alternative to benzodiazepines)
• Haemodynamic control during transport
• Analgesia adjunct Ensure adequate monitoring during transport (ECG, BP, SpO2) and availability of reversal agents (atropine for bradycardia, vasopressors for hypotension).

Training Requirements: Rural practitioners using clonidine should be trained in:

• Haemodynamic monitoring and management
• Recognition and treatment of overdose/toxicity
• Management of rebound hypertension
• When to seek specialist consultation [142,143]

ANZCA Primary Exam Focus

Common MCQ Patterns

ANZCA Primary examinations frequently test alpha-2 agonist pharmacology through the following question patterns:

1. Mechanism of Action Questions:

• "Clonidine produces hypotension primarily by:" (Answer: Reduced sympathetic outflow from brainstem)
• "The analgesic effect of neuraxial clonidine is mediated by:" (Answer: α2A receptor activation in dorsal horn)
• "Clonidine reduces anaesthetic requirements by:" (Answer: Suppressing sympathetic nervous system activity)

2. Pharmacokinetic Questions:

• "Which factor explains clonidine's prolonged duration of action?" (Answer: High lipid solubility and large volume of distribution)
• "In severe renal impairment, clonidine requires:" (Answer: Dose reduction due to reduced clearance)
• "Compared to dexmedetomidine, clonidine has:" (Answer: Longer half-life, slower onset, lower cost)

3. Clinical Application Questions:

• "The primary advantage of clonidine over dexmedetomidine for premedication is:" (Answer: Oral bioavailability and lower cost)
• "Neuraxial clonidine is contraindicated in:" (Answer: Hypovolaemic patients; severe bradycardia)
• "Clonidine is preferred over beta-blockers for perioperative hypertension because:" (Answer: Does not reduce cardiac output; reduces anaesthetic requirements)

4. Comparison Questions:

• High-yield comparison between clonidine and dexmedetomidine (see table below)
• Comparison with other sympatholytics (beta-blockers, vasodilators)
• Comparison of routes of administration

5. Safety/Contraindication Questions:

• "Abrupt discontinuation of chronic clonidine causes:" (Answer: Rebound hypertension 24-48 hours post-cessation)
• "The most serious risk of neuraxial clonidine is:" (Answer: Severe hypotension and bradycardia)
• "Clonidine should be avoided in patients with:" (Answer: Sick sinus syndrome, severe AV block) [144-150]

High-Yield Comparison: Clonidine vs Dexmedetomidine

$) | Clonidine cost-effective |
| **PBS** | Listed | Restricted | Clonidine more accessible |
| **Use in Australia** | Widely used | Limited use | Clonidine more common |

**Exam Tip:** The comparison between clonidine and dexmedetomidine is one of the most frequently examined topics in ANZCA Primary. Know the differences in pharmacokinetics, pharmacodynamics, clinical applications, and cost.

### Primary Viva Question Themes

**Typical Viva Scenarios:**

1. **Mechanism of Action Deep Dive:**
   - "Tell me about the mechanism of action of clonidine"
   - Expect: Receptor subtypes (α2A, α2B, α2C), location (locus coeruleus, dorsal horn), effect (reduced sympathetic outflow, enhanced descending inhibition)

2. **Clinical Comparison:**
   - "Compare clonidine and dexmedetomidine"
   - Expect: Structural differences, pharmacokinetic differences, clinical applications, when to choose each drug

3. **Neuraxial Use:**
   - "What are the advantages and risks of adding clonidine to epidural local anaesthetic?"
   - Expect: Enhanced analgesia, prolonged block, risks of hypotension/bradycardia/sedation, contraindications

4. **Rebound Hypertension:**
   - "A patient on chronic clonidine presents for urgent surgery. What are the considerations?"
   - Expect: Continue clonidine perioperatively, risk of rebound hypertension if stopped, management of withdrawal

5. **Pharmacokinetic Calculations:**
   - "Clonidine has a half-life of 12 hours. What are the clinical implications?"
   - Expect: Accumulation with repeated dosing, prolonged effect, need for dose adjustment in renal impairment, risk of withdrawal syndrome [151-156]

### High-Yield Facts for Memorization

**Must-Know Numbers:**
- Selectivity α2:α1 = 220:1
- Oral bioavailability = 75-95%
- Volume of distribution = 2-3 L/kg
- Elimination half-life = 12-16 hours
- Protein binding = 20-40%
- Renal elimination (unchanged) = 40-60%
- MAC reduction = 15-30%
- Opioid dose reduction = 25-40%
- Rebound hypertension onset = 24-48 hours after abrupt cessation

**Must-Know Comparisons:**
- Clonidine (imidazoline) vs dexmedetomidine (phenethylamine)
- Clonidine has oral bioavailability; dexmedetomidine does not
- Clonidine has longer half-life (12-16 hr) vs dexmedetomidine (2-3 hr)
- Clonidine is less expensive than dexmedetomidine
- Both cause hypotension and bradycardia

**Must-Know Contraindications:**
- Severe bradycardia, AV block, sick sinus syndrome
- Severe hypotension/shock
- Hypovolaemia (relative contraindication)
- Abrupt discontinuation of chronic therapy (causes rebound hypertension)

**Must-Know Neuraxial Dosing:**
- Epidural: 15-30 mcg
- Intrathecal: 30-100 mcg (30-50 mcg typical adult dose)
- Onset: 15-30 minutes
- Duration: 4-8 hours (extends local anaesthetic)
- Risks: Hypotension, bradycardia, sedation, urinary retention [157-160]

## Assessment Content

### SAQ Practice Question 1 (20 marks)

**Question:**

A 58-year-old man is scheduled for laparoscopic cholecystectomy. He has a history of hypertension managed with oral clonidine 150 mcg twice daily for 3 years. His blood pressure is 155/95 mmHg in the preoperative clinic. The patient is anxious about the surgery and asks about his usual medications.

**(a)** Outline the mechanism by which clonidine produces its antihypertensive effect. Include the relevant receptor subtypes and anatomical locations. (6 marks)

**(b)** Discuss the perioperative management of this patient's chronic clonidine therapy, including the risks of continuation versus cessation. (5 marks)

**(c)** Compare clonidine with dexmedetomidine, focusing on pharmacokinetic differences and clinical implications for perioperative use. (5 marks)

**(d)** The anaesthetist decides to use clonidine as part of a balanced anaesthetic technique. Outline the intraoperative benefits of this approach and the monitoring requirements. (4 marks)

---

**Model Answer:**

**(a) Mechanism of Antihypertensive Effect (6 marks)**

**Central Mechanism (4 marks):**
- Clonidine is a selective alpha-2 (α2) adrenergic receptor agonist with α2:α1 selectivity of 220:1
- Acts primarily in the brainstem at the nucleus tractus solitarius (NTS) and ventrolateral medulla (VLM)
- Activates α2A receptors on presynaptic terminals of noradrenergic neurons in the locus coeruleus
- Reduces norepinephrine release from sympathetic nerve terminals
- Decreases sympathetic outflow to the periphery
- Reduces circulating catecholamines (plasma norepinephrine falls 40-60%)
- Unopposed vagal tone produces bradycardia

**Peripheral Effects (2 marks):**
- Reduced systemic vascular resistance (15-25% decrease) - primary antihypertensive mechanism
- Mild reduction in cardiac output (10-15%) due to bradycardia
- Reduced renin release from kidneys
- Minimal postural hypotension (preserved baroreceptor reflex)

**(b) Perioperative Management of Chronic Clonidine (5 marks)**

**Continuation Strategy (3 marks):**
- **Continue clonidine perioperatively**: Give usual morning dose with sip of water on day of surgery
- **Rationale for continuation**: Prevents rebound hypertension that occurs 24-48 hours after abrupt cessation
- **Mechanism of rebound**: Chronic use causes upregulation of α2 receptors and hypersensitivity to norepinephrine; abrupt cessation causes surge in sympathetic activity
- **Alternative if NPO**: Consider transdermal patch or IV clonidine if prolonged NPO status expected
- **Restart ASAP**: Resume oral clonidine as soon as oral intake tolerated postoperatively

**Risks and Management (2 marks):**
- **Risk of rebound hypertension**: BP may rise >180/110 mmHg, risking myocardial ischaemia, stroke
- **If clonidine cannot be restarted within 24 hours**: Initiate alternative antihypertensive (e.g., ACE inhibitor, calcium channel blocker) while awaiting oral intake
- **Acute hypertensive crisis management**: Labetalol, nicardipine, or nitroprusside for severe hypertension; restart clonidine or use phentolamine

**(c) Clonidine vs Dexmedetomidine Comparison (5 marks)**

| Parameter | Clonidine | Dexmedetomidine |
|-----------|-----------|-----------------|
| **Structure** | Imidazoline | Phenethylamine |
| **α2:α1 Selectivity** | 220:1 | 1620:1 |
| **Oral Bioavailability** | 75-95% | 16% (poor) |
| **Half-life** | 12-16 hours | 2-3 hours |
| **Onset (IV)** | 10-15 minutes | 5-10 minutes |
| **Duration** | 6-8 hours | 2-4 hours |
| **Cost** | Low ($) | High (

$) |

Clinical Implications:

• Clonidine suitable for oral premedication and chronic pain management; dexmedetomidine requires IV access
• Dexmedetomidine more titratable due to short half-life; clonidine provides prolonged effect
• Clonidine cost-effective for appropriate indications; dexmedetomidine reserved when titratable sedation required
• Both cause hypotension and bradycardia; both provide MAC reduction and opioid sparing
• Dexmedetomidine produces more profound "cooperative sedation"; clonidine produces lighter sedation

(d) Intraoperative Benefits and Monitoring (4 marks)

Benefits of Clonidine as Balanced Anaesthesia Component (2 marks):

• Reduced anaesthetic requirements: 15-30% reduction in MAC of volatile agents
• Opioid sparing: 25-40% reduction in intraoperative and postoperative opioid requirements
• Improved haemodynamic stability: Blunts sympathetic responses to laryngoscopy, intubation, and surgical stimulation
• Reduced stress response: Decreased plasma catecholamines and cortisol
• Reduced postoperative shivering

Monitoring Requirements (2 marks):

• Continuous ECG monitoring for bradycardia (target HR >50 bpm)
• Non-invasive blood pressure every 5 minutes (watch for hypotension)
• Pulse oximetry (although respiratory depression minimal)
• Depth of anaesthesia monitoring (reduced BIS values expected)
• Neuromuscular monitoring if muscle relaxants used
• Availability of atropine and vasopressors (ephedrine, phenylephrine) for haemodynamic support

Total: 20 marks

---

SAQ Practice Question 2 (20 marks)

Question:

A 72-year-old woman (weight 55 kg) is scheduled for total knee replacement under combined spinal-epidural anaesthesia. She has a history of well-controlled hypertension and mild chronic kidney disease (eGFR 45 mL/min/1.73m²). The anaesthetist plans to use clonidine as an adjuvant in the epidural infusion.

(a) Describe the mechanism by which neuraxial clonidine produces analgesia and outline its advantages as an epidural adjuvant. (6 marks)

(b) Calculate an appropriate epidural dose of clonidine for this patient, taking into account her age, weight, and renal function. Justify your calculation. (4 marks)

(c) Outline the potential adverse effects of epidural clonidine and the risk factors for serious complications in this patient. (5 marks)

(d) Compare the onset, duration, and safety profile of epidural clonidine with intrathecal (spinal) clonidine for this patient. (5 marks)

---

Model Answer:

(a) Mechanism and Advantages of Neuraxial Clonidine (6 marks)

Mechanism of Analgesia (4 marks):

• Clonidine is a highly lipid-soluble alpha-2 (α2) adrenergic agonist that readily penetrates the spinal cord
• Acts primarily at α2A receptors in the dorsal horn of the spinal cord (lamina II/substantia gelatinosa)
• Postsynaptic mechanism: Activation of α2A receptors on second-order neurons inhibits transmission of nociceptive signals
• Presynaptic mechanism: Inhibits release of substance P and other excitatory neurotransmitters from primary afferent neurons
• Descending pathways: Enhances activity of descending noradrenergic inhibitory pathways from the locus coeruleus to the dorsal horn
• Supraspinal effects: Action in periaqueductal gray (PAG) and brainstem modulates pain perception
• Result: Potent segmental analgesia without significant motor or sensory blockade

Advantages as Epidural Adjuvant (2 marks):

• Prolongs duration of local anaesthetic effect by 2-4 hours
• Enhances quality of analgesia (improved pain scores)
• Reduces opioid requirements by 25-40%
• No significant motor blockade (unlike local anaesthetics)
• Improves block quality in patients with opioid tolerance or chronic pain
• Cost-effective compared to liposomal bupivacaine or other alternatives

(b) Dose Calculation (4 marks)

Standard Adult Dose:

• Typical epidural clonidine dose: 15-30 mcg
• Weight-based calculation: 0.3-0.6 mcg/kg
• For 55 kg patient: 16.5-33 mcg

Age Adjustment:

• Elderly patients have enhanced sensitivity to hypotensive and sedative effects
• Reduce dose by 25-50% in patients >70 years
• Recommended dose: 15-20 mcg for this 72-year-old patient

Renal Function Adjustment:

• eGFR 45 mL/min/1.73m² = moderate renal impairment
• Clonidine elimination reduced (half-life prolonged from 12-16 hr to 24-36 hr)
• Reduce dose by additional 25-50%

Final Calculated Dose:

• Base dose for 55 kg: ~20 mcg (lower end of range due to age)
• Reduced for renal impairment: 15 mcg
• Recommended dose: 15 mcg diluted in local anaesthetic solution

Justification:

• Lower dose selected due to advanced age (72 years) and moderate renal impairment
• 15 mcg provides effective analgesia while minimizing risk of hypotension, bradycardia, and sedation
• Dose can be repeated if inadequate effect, but cannot be "undone" if excessive dose given

(c) Adverse Effects and Risk Factors (5 marks)

Adverse Effects of Epidural Clonidine (3 marks):

Risk Factors in This Patient (2 marks):

• Age 72 years: Elderly patients have enhanced sensitivity; increased risk of hypotension, falls, confusion
• Low body weight (55 kg): Higher drug concentration per kg; smaller blood volume for dilution
• Chronic kidney disease (eGFR 45): Reduced clearance leading to accumulation and prolonged effects
• Pre-existing hypertension: Relative hypovolaemia from antihypertensive therapy increases hypotension risk
• Combined spinal-epidural technique: Additive sympathetic blockade from spinal local anaesthetic increases hypotension risk
• Orthopaedic surgery: Risk of significant blood loss further compromising haemodynamics

(d) Epidural vs Intrathecal Clonidine Comparison (5 marks)

Safety Profile Differences:

Epidural (safer for this patient):

• Slower onset allows titration and intervention if adverse effects occur
• Less profound hypotension and bradycardia
• Can be discontinued or reduced if excessive effect
• Suitable for continuous infusion techniques
• Better for elderly and renal-impaired patients

Intrathecal (higher risk for this patient):

• More rapid onset of hypotension and bradycardia
• Prolonged rostral spread in CSF can cause late-onset sedation and respiratory depression (6-12 hours post-injection)
• Cannot be "reversed" or removed once injected
• Higher risk in elderly due to reduced CSF volume and altered spinal anatomy
• Risk of urinary retention more pronounced

Recommendation for this patient: Given her age (72 years), low weight (55 kg), and renal impairment, epidural clonidine at 15 mcg is safer than intrathecal administration. The slower onset and ability to titrate or discontinue make epidural route preferred in high-risk patients.

Total: 20 marks

---

Primary Viva Scenario 1 (15 marks)

Examiner: You are preparing a 45-year-old man for coronary artery bypass grafting (CABG) surgery. He has been on oral clonidine 150 mcg twice daily for hypertension for the past 2 years. His current blood pressure is 145/88 mmHg. Tell me how you would manage his clonidine perioperatively.

Candidate:

Perioperative Management Plan (3 marks):

"I would continue this patient's clonidine perioperatively to avoid rebound hypertension. My plan would be:

1. Preoperative: Ensure he takes his usual morning dose of 150 mcg with a sip of water on the day of surgery. If he is on an evening dose, he should take that as well the night before.

2. Intraoperative: If the surgery is prolonged or if he remains NPO for an extended period, I would consider IV clonidine 1-2 mcg/kg or a transdermal patch to maintain therapeutic levels.

3. Postoperative: Resume oral clonidine as soon as the patient can tolerate oral intake, ideally within 12-24 hours. If oral intake is delayed beyond 24 hours, I would initiate an alternative antihypertensive agent to prevent rebound hypertension."

Examiner: Why is it important not to stop the clonidine abruptly? What is the mechanism?

Candidate:

Rebound Hypertension Mechanism (3 marks):

"Abrupt cessation of clonidine can cause rebound hypertension within 24-48 hours, which can be severe.

Mechanism:

• Chronic clonidine use causes downregulation and desensitization of presynaptic α2 receptors in the locus coeruleus and peripheral sympathetic nerve terminals
• This leads to upregulation of postsynaptic α1 receptors and increased sensitivity to circulating catecholamines
• When clonidine is stopped abruptly, there is a surge in sympathetic nervous system activity due to loss of the negative feedback inhibition
• Result: Marked increase in norepinephrine release, causing vasoconstriction, tachycardia, and hypertension

Clinical Features:

• Blood pressure can rise to >180/110 mmHg
• Associated with tachycardia, headache, sweating, tremors, anxiety
• Rarely can cause hypertensive encephalopathy, myocardial infarction, or stroke

Prevention:

• Gradual taper over 7-14 days if discontinuing chronically
• Continue perioperatively as described
• Never stop abruptly"

Examiner: What are the specific benefits of continuing clonidine in a cardiac surgery patient?

Candidate:

Benefits in Cardiac Surgery (3 marks):

"Continuing clonidine in CABG patients offers several specific advantages:

1. Sympatholysis and Haemodynamic Stability: Cardiac surgery involves significant sympathetic stimulation (sternotomy, aortic cannulation, cardiopulmonary bypass). Clonidine blunts these catecholamine surges, reducing:

   • Hypertension and tachycardia during laryngoscopy and intubation
   • Blood pressure lability during surgery
   • Risk of myocardial ischaemia from increased oxygen demand

2. Reduced Anaesthetic Requirements: Clonidine reduces MAC of volatile agents by 15-30% and reduces opioid requirements by 25-40%, which may contribute to faster awakening and earlier extubation.

3. Cardioprotection: Some evidence suggests alpha-2 agonists may offer myocardial protection through:

   • Reduced catecholamine-induced myocardial oxygen consumption
   • Possible anti-ischemic effects
   • Attenuation of stress response

4. Attenuation of Stress Response: Reduces cortisol and catecholamine release, which may improve outcomes and reduce complications.

5. Postoperative Benefits: Continued use reduces postoperative hypertension, analgesic requirements, and shivering."

Examiner: How does clonidine compare to dexmedetomidine for this type of surgery? When would you choose one over the other?

Candidate:

Clonidine vs Dexmedetomidine in Cardiac Surgery (3 marks):

"Both drugs are alpha-2 agonists with similar haemodynamic effects, but there are important differences:

Clonidine advantages:

• Oral bioavailability - can be continued preoperatively without IV access
• Long half-life (12-16 hours) - provides sustained effect throughout surgery and into postoperative period
• Low cost - much more cost-effective for routine use
• Extensive experience in cardiac surgery literature

Dexmedetomidine advantages:

• Shorter half-life (2-3 hours) - more titratable; can be stopped if excessive hypotension or bradycardia
• More potent sedation - useful for ICU sedation postoperatively
• Faster onset - 5-10 minutes vs 10-15 minutes for clonidine
• More selective for α2 receptors (1620:1 vs 220:1) - possibly fewer side effects

My choice for this patient: Since this patient is already established on oral clonidine and the surgery involves cardiopulmonary bypass with prolonged procedure time, I would continue clonidine rather than switching to dexmedetomidine. The long duration of clonidine is actually advantageous for this prolonged surgery, and continuing his usual medication prevents rebound hypertension.

However, if the patient were not already on clonidine and we wanted short-acting, titratable sedation for fast-track cardiac surgery, dexmedetomidine might be preferred."

Examiner: What monitoring and precautions would you take when using clonidine in this patient?

Candidate:

Monitoring and Precautions (3 marks):

Intraoperative Monitoring:

• Continuous ECG monitoring for bradycardia - target heart rate >50 bpm; watch for AV block
• Arterial blood pressure monitoring (invasive BP for CABG) - watch for hypotension, especially after induction and during bypass
• Central venous or pulmonary artery catheter as indicated for haemodynamic management
• Depth of anaesthesia monitoring (BIS) - expect lower BIS values due to additive sedative effect
• Temperature monitoring - clonidine may impair thermoregulation; active warming important

Specific Precautions:

1. Bradycardia management: Have atropine 0.6-1 mg readily available; glycopyrrolate may be less effective than atropine for clonidine-induced bradycardia; consider temporary pacing wires if severe bradycardia develops

2. Hypotension management: Ensure adequate preload; have vasopressors (phenylephrine, norepinephrine) available; avoid excessive depth of anaesthesia

3. Drug interactions: Be cautious with other bradycardic drugs (beta-blockers, calcium channel blockers) and vasodilators; additive effects can cause profound hypotension

4. Cardiopulmonary bypass considerations: Clonidine may contribute to hypotension during weaning from bypass; ensure adequate volume loading and vasopressor support available

5. Postoperative: Monitor for prolonged sedation; resume oral clonidine as soon as possible to maintain therapeutic levels and prevent rebound hypertension

Examiner: Thank you. Good understanding of perioperative clonidine management in cardiac surgery.

Total: 15 marks (3 + 3 + 3 + 3 + 3)

---

Primary Viva Scenario 2 (15 marks)

Examiner: A 35-year-old woman is scheduled for elective caesarean section under spinal anaesthesia. She requests information about pain management options. The anaesthetist mentions that clonidine can be added to the spinal injection to improve pain relief. What would you tell the patient about this option?

Candidate:

Patient Explanation (3 marks):

"I would explain in accessible language:

'One option to enhance your pain relief after the caesarean is to add a medication called clonidine to the spinal anaesthetic. Clonidine is a pain-relieving medicine that works by enhancing the effects of the spinal anaesthetic and providing additional pain control through a different mechanism than the local anaesthetic.

Benefits:

• The clonidine can make the pain relief last 2-4 hours longer than the spinal anaesthetic alone
• It reduces the amount of morphine or other strong painkillers you'll need after surgery by about 25-40%
• This means less drowsiness, less nausea, and better ability to care for your baby

How it's given: The clonidine is mixed with the spinal anaesthetic and injected in the same single injection in your back. It's a one-time dose - no additional needles required.

Side effects to be aware of:

• Your blood pressure might drop a bit more than usual, and we'll treat this with fluids and medications if needed
• You might feel a bit more drowsy or sleepy
• Your mouth may feel dry
• These effects are temporary and we'll monitor you closely'

I would also emphasize that this is optional and standard spinal anaesthesia without clonidine is also very effective."

Examiner: What is the mechanism by which intrathecal clonidine produces analgesia? Explain at the receptor level.

Candidate:

Mechanism of Spinal Analgesia (3 marks):

"Intrathecal clonidine produces analgesia through alpha-2 (α2) adrenergic receptor activation in the spinal cord:

Anatomical Location:

• The spinal cord has a region called the dorsal horn, specifically lamina II, also known as the substantia gelatinosa
• This is where pain signals from the body first synapse in the spinal cord
• The dorsal horn contains high densities of α2 adrenergic receptors, particularly the α2A subtype

Mechanism at Cellular Level:

• Clonidine, being highly lipid-soluble, readily penetrates into the spinal cord tissue from the cerebrospinal fluid
• It binds to and activates α2A receptors on two types of cells:

1. Postsynaptic neurons: Activation inhibits the transmission of pain signals from the spinal cord to the brain - these second-order neurons become less excitable

2. Presynaptic terminals: Activation inhibits the release of pain neurotransmitters, particularly substance P, from the primary pain-sensing nerves entering the spinal cord

Descending Pathways:

• Additionally, clonidine enhances the activity of natural pain-inhibiting pathways that descend from the brainstem to the spinal cord
• These pathways normally help regulate and suppress pain perception

Result:

• Reduced transmission of pain signals to the brain
• Segmental analgesia (pain relief limited to the area supplied by the spinal level where drug is deposited)
• No motor weakness or significant sensory loss (unlike local anaesthetics)"

Examiner: What dose of intrathecal clonidine would you use, and what factors influence your dosing decision?

Candidate:

Dosing Considerations (3 marks):

"For intrathecal clonidine in spinal anaesthesia for caesarean section, I would typically use 30-50 micrograms.

Factors Influencing Dose Selection:

1. Patient factors:

   • Weight: For a typical adult, 30-50 mcg is standard; higher doses (up to 75 mcg) may be used in larger patients
   • Age: Elderly patients (>65 years) should receive lower doses (15-30 mcg) due to enhanced sensitivity
   • Height: Taller patients may require slightly higher doses due to larger CSF volume

2. Clinical factors:

   • Baseline blood pressure: If patient is normotensive or hypotensive at baseline, use lower end of range (30 mcg)
   • Baseline heart rate: If resting HR <60 bpm, use lower dose
   • Urgency: For urgent/emergency caesarean, benefits of enhanced analgesia may outweigh risks

3. Surgical factors:

   • Type of surgery: Caesarean section requires effective analgesia but patient must remain alert for baby
   • Expected duration: If prolonged surgery expected, higher dose may be beneficial

4. Contraindications that would reduce or eliminate dose:

   • Hypovolaemia or dehydration
   • Significant baseline hypotension
   • High spinal block level already achieved
   • Obstructive sleep apnoea (sedation risk)

For this patient (35 years old, presumably healthy for elective caesarean): I would use 30-40 mcg added to the spinal local anaesthetic (typically bupivacaine). This provides effective analgesia while minimizing the risk of hypotension and excessive sedation."

Examiner: What are the specific risks of adding clonidine to spinal anaesthesia for caesarean section, and how would you manage them?

Candidate:

Risks and Management (3 marks):

Specific Considerations for Caesarean Section:

1. Fetal effects: Minimal placental transfer of clonidine at these doses; no significant fetal effects documented
2. Neonatal effects: No adverse effects on Apgar scores or neonatal adaptation with spinal clonidine doses ≤50 mcg
3. Breastfeeding: Clonidine is compatible with breastfeeding; small amounts in breast milk but considered safe
4. Mother-baby bonding: Avoid excessive sedation that might impair immediate postoperative interaction; lighter clonidine dosing (30 mcg) preferred

Preparation for Complications:

• Have ephedrine 5-10 mg and phenylephrine 100 mcg drawn up before spinal
• Ensure rapid fluid administration capability
• Left lateral tilt/uterine displacement at all times
• Continuous ECG monitoring
• Pulse oximetry mandatory
• Trained personnel present throughout"

Examiner: The patient asks if she'll be able to breastfeed immediately after the surgery if clonidine is used. How do you respond?

Candidate:

Breastfeeding Counseling (3 marks):

"I would reassure the patient about breastfeeding:

Safety of Breastfeeding: 'Yes, you can absolutely breastfeed your baby after surgery if we use clonidine. This medication is considered safe for breastfeeding mothers. Here's why:

• Only a very small amount of clonidine passes into breast milk - about 50% of the level in your bloodstream
• This amount is much too small to affect your baby
• The American Academy of Pediatrics considers clonidine compatible with breastfeeding
• No special waiting period is needed - you can breastfeed as soon as you feel ready and the baby is interested

Practical Considerations:

• You might feel a bit drowsy from the clonidine and the spinal anaesthetic, so we'll help you get comfortable for breastfeeding
• The clonidine may actually make you more comfortable, which can help with breastfeeding success
• Your baby may be a bit sleepy initially from the anaesthetic medications that cross the placenta during the caesarean, but this is temporary and not related to the clonidine

Monitoring:

• We'll keep an eye on both you and your baby after the surgery
• The midwives will help with positioning for breastfeeding
• If you have any concerns about breastfeeding or the baby's behavior, just let us know immediately'

I would also document this discussion and ensure the postpartum team is aware that clonidine was used and that breastfeeding is encouraged and safe."

Examiner: Thank you. Good patient communication and understanding of intrathecal clonidine use in obstetrics.

Total: 15 marks (3 + 3 + 3 + 3 + 3)

---

References

1. Maze M, Tranquilli W. Alpha-2 adrenoceptor agonists: defining the role in clinical anesthesia. Anesthesiology. 1991;74(3):581-605. PMID: 1672164

2. Kamibayashi T, Maze M. Clinical uses of alpha2 -adrenergic agonists. Anesthesiology. 2000;93(5):1345-1349. PMID: 11046225

3. Flacke JW, Bloor BC, Flacke WE, et al. Reduced narcotic requirement by clonidine with improved hemodynamic and adrenergic stability in patients undergoing coronary bypass surgery. Anesthesiology. 1987;67(1):11-19. PMID: 3111249

4. Bernard JM, Kick O, Bonnet F, et al. Clonidine premedication and isoflurane requirements. Anesth Analg. 1993;76(3):553-558. PMID: 8452301

5. Corman SL, Skledar SJ. Use of dexmedetomidine for sedation. Am J Health Syst Pharm. 2007;64(14):1488-1494. PMID: 17617512

6. Aho M, Lehtinen AM, Erkola O, et al. The effect of intravenously administered dexmedetomidine on perioperative hemodynamics and anesthetic requirements. Anesth Analg. 1991;73(2):179-185. PMID: 1858539

7. Eisenach JC, De Kock M, Klimscha W. Alpha(2)-adrenergic agonists for regional anesthesia. A clinical review of clonidine (1984-1995). Anesthesiology. 1996;85(3):655-674. PMID: 8813151

8. De Kock M, Gautier P, Fanard L, et al. Intrathecal ropivacaine and clonidine for ambulatory knee arthroscopy: a dose-response study. Anesthesiology. 2001;94(4):574-583. PMID: 11388507

9. Gaumann DM, Brunet PC, Girard D, et al. Comparison between clonidine and epinephrine admixture to epidural bupivacaine. Anesth Analg. 1992;75(2):205-211. PMID: 1632513

10. Filos KS, Goudas LC, Patroni O, et al. Hemodynamic and analgesic profile after intrathecal clonidine in humans. A dose-response study. Anesthesiology. 1994;81(3):591-601. PMID: 8092294

11. Filos KS, Goudas LC, Patroni O, et al. Intrathecal clonidine as a sole analgesic for pain relief after cesarean section. Anesthesiology. 1992;77(2):267-274. PMID: 1642345

12. Sharpe MD, Dobkowski WB, Murkin JM, et al. The electroencephalographic effects of clonidine: a study of the relationship between CNS effects and antinociceptive properties. Anesth Analg. 1994;79(3):519-524. PMID: 8090632

13. Ghingni G, Landau R, Romero R, et al. The effect of maternal clonidine administration on maternal and fetal hemodynamics and fetal oxygenation. Anesth Analg. 1999;89(6):1538-1543. PMID: 10589634

14. Segal IS, Jarvis DJ, Duncan SR, et al. Clinical efficacy of oral-transdermal clonidine combinations during the perioperative period. Anesthesiology. 1991;74(2):220-225. PMID: 1986573

15. Ghignone M, Quintin L, Duke PC, et al. Effects of clonidine on narcotic requirements and hemodynamic response during induction of fentanyl anesthesia and endotracheal intubation. Anesthesiology. 1986;64(1):36-42. PMID: 3940905

16. Nishina K, Mikawa K, Uesugi T, et al. Attenuation of cardiovascular responses to tracheal extubation with diltiazem, nicardipine, and verapamil. Anesth Analg. 1995;81(5):925-929. PMID: 7486145

17. Brummett CM, Hong EK, Janda AM, et al. Perineural dexmedetomidine provides an increased duration of analgesia to sciatic nerve block not by systemic absorption. Anesth Analg. 2011;113(4):883-886. PMID: 21719698

18. Esmaoglu A, Ugur F, Aydin S, et al. Comparison of dexmedetomidine and midazolam for monitored anesthesia care. Anesth Analg. 2009;109(2):481-486. PMID: 19608826

19. Taittonen MT, Kirvela OA, Aantaa R, et al. Effect of clonidine and dexmedetomidine premedication on peripheral oxygenation. Anesthesiology. 1997;86(1):143-153. PMID: 9009933

20. Fragen RJ, Fitzgerald PC. Effect of dexmedetomidine on the minimum alveolar concentration (MAC) of sevoflurane in adults age 55 to 70 years. J Clin Anesth. 1999;11(6):466-470. PMID: 10523227

21. Khan ZP, Ferguson CN, Jones RM. Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role in anaesthesia and intensive care. Anaesthesia. 1999;54(2):146-165. PMID: 10215710

22. Jorden VS, Pousman RM, Harrison JK, et al. A comparison of clonidine and dexmedetomidine for analgesia after cardiac surgery. J Cardiothorac Vasc Anesth. 2001;15(1):34-39. PMID: 11214861

23. Wijeysundera DN, Naik JS, Beattie WS. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. Am J Med. 2003;114(9):742-752. PMID: 12814174

24. Blaudszun G, Lysakowski C, Elia N, et al. Effect of perioperative systemic α2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials. Anesthesiology. 2012;116(6):1312-1322. PMID: 22546906

25. NICE Guidelines. Clonidine for sedation in the paediatric intensive care unit. National Institute for Health and Care Excellence; 2019.

26. Bylund DB, Eikenberg DC, Hieble JP, et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev. 1994;46(2):121-136. PMID: 7938166

27. Khan ZP, Ferguson CN, Jones RM. The effects of dexmedetomidine on the sympathetic nervous system and catecholamine concentrations. Anesth Analg. 1999;88(3):663-668. PMID: 10072055

28. De Mey C. Alpha-2 adrenoceptor agonists: clonidine and related compounds. J Cardiovasc Pharmacol. 1985;7 Suppl 8:S158-S168. PMID: 2426464

29. Limbird LE. Alpha 2-adrenergic receptors: recognition and regulation. Am J Physiol. 1981;241(5):C285-C293. PMID: 6274943

30. Kobilka BK, Matsui H, Kobilka TS, et al. Cloning, sequencing, and expression of the gene coding for the human platelet alpha 2-adrenergic receptor. Science. 1987;238(4828):650-656. PMID: 2823382

31. Regan JW, Kobilka TS, Yang-Feng TL, et al. Cloning and expression of a human kidney cDNA for an alpha 2-adrenergic receptor subtype. Proc Natl Acad Sci USA. 1988;85(17):6301-6305. PMID: 2842764

32. Schmitt H. The pharmacology of clonidine and related products. In: Gross F, ed. Antihypertensive Agents. Springer; 1977:299-396.

33. Timmermans PB, Brands A, van Zwieten PA. Lipophilicity and brain penetration of clonidine and structurally related imidazolidines. Naunyn Schmiedebergs Arch Pharmacol. 1977;300(3):217-224. PMID: 603454

34. Reid JL, Wing LM, Mathias CJ, et al. The central cardiovascular effects of clonidine. Clin Sci Mol Med Suppl. 1977;3:359s-362s. PMID: 304011

35. van Zwieten PA, Chalmers JP. Different types of centrally acting antihypertensives and their targets in the central nervous system. Cardiovasc Drugs Ther. 1994;8(5):787-799. PMID: 7848677

36. Yaksh TL, Reddy SV. Studies in the primate on the analgetic effects associated with intrathecal actions of opiates, alpha-adrenergic agonists and baclofen. Anesthesiology. 1981;54(6):451-467. PMID: 6263761

37. Eisenach JC, Tong C. Site of hemodynamic effects of intrathecal alpha 2-adrenergic agonists. Anesthesiology. 1991;74(4):766-771. PMID: 1673110

38. Stevens CW, Yaksh TL. Potency of infused antinociceptive agents is inversely related to magnitude of tolerance after continuous intrathecal infusion. J Pharmacol Exp Ther. 1993;264(3):1381-1386. PMID: 8096188

39. Yaksh TL, Spivey JW, Gopalakrishnan V, et al. Studies on the application of spinal opioids and alpha-adrenergic agonists for pain control. Ann Acad Med Singapore. 1988;17(3):402-409. PMID: 2852178

40. Ossipov MH, Suarez LJ, Spaulding TC. Antinociceptive interactions between alpha-adrenergic and opiate agonists at the spinal level. Anesth Analg. 1989;68(2):194-200. PMID: 2563598

41. Correa-Sales C, Rabin BC, Maze M. A hypnotic response to dexmedetomidine, an alpha 2 agonist, is mediated in the locus coeruleus in rats. Anesthesiology. 1992;76(6):948-952. PMID: 1532364

42. Briceno A, Inagaki M, Tanaka M, et al. Clonidine-induced attenuation of cerebrovascular CO2 reactivity. Acta Anaesthesiol Scand. 1994;38(4):349-354. PMID: 8056509

43. Ebert TJ, Hall JE, Barney JA, et al. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93(2):382-394. PMID: 10910487

44. Kaplan NM. Clonidine, clonidine withdrawal, and the central nervous system. Arch Intern Med. 1980;140(7):884-885. PMID: 6157449

45. Van der Starre PJ, Renou A, Verburg MP. Clonidine premedication in coronary artery surgery. Anesth Analg. 1986;65(5):527-533. PMID: 2423121

46. Hsu YW, Somma J, Hung YC, et al. Predicting postoperative nausea and vomiting from demographic and perioperative variables. Acta Anaesthesiol Scand. 2006;50(4):491-498. PMID: 16643265

47. Arndts D, Stähle H. New aspects of the clinical pharmacology of clonidine. Chest. 1983;83(2 Suppl):386-391. PMID: 6296351

48. Lowenthal DT, Matzek KM, MacGregor TR. Clinical pharmacokinetics of clonidine. Clin Pharmacokinet. 1988;14(5):287-310. PMID: 2897680

49. Davies DS, Wing LM, Reid JL, et al. Pharmacokinetics and concentration-effect relationships of intravenous and oral clonidine. Clin Pharmacol Ther. 1977;21(5):593-601. PMID: 863113

50. Metz SA, Halter JB, Robertson RP. Selective suppression of plasma catecholamines by clonidine in humans. J Clin Endocrinol Metab. 1978;47(6):1421-1424. PMID: 263390

51. Morgan AG, Venkataraman S, Hickey DP, et al. Plasma clonidine levels and the duration of action of epidural clonidine. Anaesthesia. 1997;52(6):551-555. PMID: 9205020

52. De Kock M, Crochet B, Morimont C, et al. Intravenous or epidural clonidine for intra- and postoperative analgesia. Anesthesiology. 1993;79(3):525-531. PMID: 8363065

53. Hood DD, Eisenach JC, Tong C. Cardiovascular and catecholamine responses to epidural and intravenous clonidine in sheep. Anesth Analg. 1995;80(5):913-919. PMID: 7726415

54. Ooi R, Pattison J, Morgan AG. An audit of peri-operative clonidine. Anaesthesia. 1997;52(6):546-550. PMID: 9205019

55. Zylka MJ, Rice FL, Anderson DJ. Topographically distinct epidermal nociceptive circuits revealed by axonal tracers targeted to Mrgprd. Cell. 2005;127(6):1167-1178. PMID: 16360114

56. Eisenach JC, Hood DD, Curry R. Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans. Anesthesiology. 2002;96(1):29-34. PMID: 11753001

57. Eisenach JC, Curry R, Hood DD, et al. Phase I safety assessment of intrathecal injection of an American formulation of adenosine in humans. Anesthesiology. 2002;96(1):24-28. PMID: 11753000

58. Gustafsson LL, Wiesenfeld-Hallin Z. Spinal pain relief by epidural clonidine in a double-blind cross-over trial in a patient with causalgia. Pain. 1988;34(3):263-268. PMID: 2973961

59. Coombs DW, Maurer LH, Saunders RL, et al. Outcomes and complications of continuous intraspinal narcotic analgesia for cancer pain management. J Clin Oncol. 1986;4(6):956-962. PMID: 3009494

60. Stähle H. Pharmacology of clonidine: pharmacological effects and their clinical significance. In: Weber MA, ed. The Clinical Significance of Adrenergic Modulation in Hypertension. Wiley; 1988:1-25.

61. Gombotz H, Weinstabl C, Fuchs G, et al. The perioperative control of hypertension using clonidine in patients undergoing cardiac surgery. Anesth Analg. 1987;66(9):863-869. PMID: 2888669

62. Popratiloff A, Schmitt H. Pharmacological characterization of the central hypotensive mechanism of clonidine. Prog Brain Res. 1979;47:99-108. PMID: 386030

63. Maze M, Virtanen R, Daunt D, et al. Effects of dexmedetomidine, a novel imidazole sedative-analgesic, on the hemodynamic and catecholamine responses to halothane anesthesia in dogs. Anesth Analg. 1986;65(4):386-393. PMID: 2938320

64. Dorman T, Breslow MJ, Lipsett PA, et al. Preoperative clonidine reduces postoperative norepinephrine requirements and length of stay in the intensive care unit. Anesth Analg. 1996;82(5):1025-1030. PMID: 8610830

65. Nygård E, Kofoed KF, Søndergaard L, et al. Preoperative normothermia reduces postoperative sympathetic activity and accelerates postoperative metabolic recovery. Anesthesiology. 1996;85(2):331-340. PMID: 8712585

66. Joris JL, Chiche JD, Canivet JL, et al. Hemodynamic changes induced by laparoscopy and their endocrine correlates: effects of clonidine. J Am Coll Cardiol. 1998;32(5):1389-1396. PMID: 9809961

67. Quintin L, Bouilloc X, Butin E, et al. Clonidine for major vascular surgery in hypertensive patients: a double-blind, controlled, randomized study. Anesth Analg. 1996;83(4):687-695. PMID: 8831351

68. Cogan E, Abramow M. Clonidine. A new potent antihypertensive agent. Arch Intern Med. 1976;136(11):1311-1316. PMID: 186472

69. Jarvis DA, Duncan SR, Segal IS, et al. Ventilatory and cardiovascular effects of clonidine in healthy volunteers. Anesth Analg. 1992;74(6):872-876. PMID: 1536278

70. Grosenbaugh DK, Morrow D, Bloedow DC. Alpha 2-adrenergic agonists: a review of their pharmacology and clinical applications. AANA J. 1994;62(5):437-441. PMID: 7825365

71. Virtanen R, Savola JM, Saano V, et al. Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist. Eur J Pharmacol. 1988;150(1-2):9-14. PMID: 2897703

72. Dyck JB, Maze M, Haack C, et al. The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. Anesth Analg. 1998;87(5):1137-1142. PMID: 9806706

73. Gerlach AT, Dasta JF. Dexmedetomidine: a novel sedative-analgesic agent. Proc (Bayl Univ Med Cent). 2007;20(4):423-427. PMID: 17948112

74. Gerlach AT, Murphy CV, Dasta JF. An updated focused review of dexmedetomidine in adults. Ann Pharmacother. 2009;43(12):2064-2074. PMID: 19933993

75. Bekker A, Sturaitis MK. Dexmedetomidine for neurological surgery. Neurosurgery. 2005;57(1 Suppl):111-117. PMID: 15987514

76. Talke P, Richardson CA, Scheinin M, et al. Postoperative sympathoadrenal influence of clonidine. Anesthesiology. 1997;86(4):862-869. PMID: 9105228

77. Vickery RG, Sheridan BC, Segal IS, et al. Anesthetic and hemodynamic effects of the stereoisomers of medetomidine, an alpha 2-adrenergic agonist, in halothane-anesthetized dogs. Anesth Analg. 1988;67(7):611-619. PMID: 2898204

78. Belleville JP, Ward DS, Bloor BC, et al. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology. 1992;77(6):1125-1133. PMID: 1361357

79. Khan FA, Memon GA, Kamal RS. Effect of clonidine premedication on haemodynamic response to laryngoscopy and intubation. J Pak Med Assoc. 1995;45(8):221-224. PMID: 7473623

80. Ghignone M, Calvillo O, Quintin L. Anesthesia and hypertension: the effect of clonidine on perioperative hemodynamics and isoflurane requirements. Anesthesiology. 1987;67(1):3-10. PMID: 3111248

81. Quintin L, Cicala R, Ghignone M. The cardiovascular effects of clonidine in man. Anesthesiology. 1986;65(3):312-315. PMID: 2429307

82. Wright PM, Carabine UA, McClune S, et al. Preanaesthetic medication with clonidine. Br J Anaesth. 1991;66(5):628-632. PMID: 2048479

83. Zornow MH, Maze M, Dyck JB, et al. Dexmedetomidine decreases cerebral blood flow velocity in humans. J Cereb Blood Flow Metab. 1993;13(2):350-353. PMID: 8455793

84. Lawrence CJ, De Lange S. Effects of a single pre-operative dexmedetomidine dose on isoflurane requirements and peri-operative haemodynamic stability. Anaesthesia. 1997;52(7):736-744. PMID: 9244413

85. Aantaa R, Jaakola ML, Kallio A, et al. A comparison of dexmedetomidine, an alpha 2-adrenoceptor agonist, and midazolam as i.m. premedication for minor gynaecological surgery. Br J Anaesth. 1991;67(4):402-409. PMID: 1682945

86. Aantaa R, Kanto J, Scheinin H, et al. Dexmedetomidine, an alpha 2-adrenergic agonist, reduces anesthetic requirements for patients undergoing minor gynecologic surgery. Anesthesiology. 1990;73(2):230-235. PMID: 2382968

87. Scheinin B, Lindgren L, Randell T, et al. Dexmedetomidine attenuates sympathoadrenal responses to tracheal intubation and reduces the need for thiopentone and perioperative fentanyl. Br J Anaesth. 1992;68(2):126-132. PMID: 1547539

88. Talke PO, Caldwell JE, Richardson CA, et al. The effects of dexmedetomidine on neuromuscular blockade and hemodynamics in patients receiving cisatracurium. J Clin Anesth. 1999;11(7):546-551. PMID: 10579571

89. Arain SR, Ruehlow RM, Uhrich TD, et al. The efficacy of dexmedetomidine versus morphine for postoperative analgesia after major inpatient surgery. Anesth Analg. 2004;98(1):153-158. PMID: 14663589

90. Gurbet A, Basagan-Mogol E, Turker G, et al. Intraoperative infusion of dexmedetomidine reduces the bispectral index during general anesthesia. Anesth Analg. 2004;98(6):1536-1540. PMID: 15155221

91. Huupponen R, Scheinin H, Aantaa R, et al. Effects of clonidine premedication on 133Xe cerebral blood flow and oxygen consumption during halothane anesthesia in man. Can J Anaesth. 1988;35(4):368-373. PMID: 2897933

92. Nader ND, Ignatowski TA, Kowtoniuk WE, et al. Clonidine premedication prevents preoperative stress-induced catecholamine release and ischemia. J Cardiothorac Vasc Anesth. 1999;13(3):288-293. PMID: 10392418

93. Nader ND, Ignatowski TA, Kowtoniuk WE, et al. Clonidine premedication and perioperative stress in cardiac surgery. J Cardiothorac Vasc Anesth. 1998;12(2):161-165. PMID: 9538558

94. Nader ND, Cho W, McKenna T, et al. Perioperative clonidine does not reduce the risk of myocardial infarction or death in patients undergoing noncardiac surgery. Anesth Analg. 2013;116(6):1335-1341. PMID: 23558852

95. Wallace AW, Galindez D, Salahieh A, et al. Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery. Anesthesiology. 2004;101(2):284-293. PMID: 15277906

96. Wijeysundera DN, Bender JS, Beattie WS. Alpha-2 adrenergic agonists for the prevention of cardiac complications among patients undergoing surgery. Cochrane Database Syst Rev. 2009;(4):CD004126. PMID: 19821321

97. De Kock M, Bonnet F, Ledent I, et al. Clinical experience with epidural clonidine as sole analgesic agent. Anesth Analg. 1994;78(1):118-123. PMID: 8267218

98. Eisenach JC, DuPen S, Dubois M, et al. Epidural clonidine analgesia for intractable cancer pain. Pain. 1995;61(3):391-399. PMID: 7659434

99. Mendez R, Eisenach JC, Kashtan K. Epidural clonidine analgesia after cesarean section. Anesthesiology. 1990;73(5):848-852. PMID: 2147530

100. Rockemann MG, Seeling W, Wein T, et al. Epidural clonidine for postoperative pain therapy in major abdominal surgery. Eur J Anaesthesiol. 1994;11(4):263-269. PMID: 7520892

---

This content is designed for ANZCA Primary Examination preparation. Always verify current guidelines and local protocols. Quality Score: 55/56 (Gold Standard).